Goodman Financial Corp Acquires 48,405 Shares of QuidelOrtho Corporation $QDEL

Goodman Financial Corp increased its holdings in QuidelOrtho Corporation (NASDAQ:QDEL) by 12.5% during the first quarter, HoldingsChannel.com reports. The institutional investor owned 437,157 shares of the company’s stock after acquiring an additional 48,405 shares during the quarter. Goodman Financial Corp’s holdings in QuidelOrtho were worth $7,182,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently added to or reduced their stakes in the company. Global Retirement Partners LLC increased its holdings in QuidelOrtho by 3,691.7% during the fourth quarter. Global Retirement Partners LLC now owns 910 shares of the company’s stock valued at $26,000 after buying an additional 886 shares during the last quarter. Camelot Portfolios LLC purchased a new position in shares of QuidelOrtho during the 4th quarter worth $29,000. Hantz Financial Services Inc. grew its position in shares of QuidelOrtho by 50.3% during the 4th quarter. Hantz Financial Services Inc. now owns 1,082 shares of the company’s stock valued at $31,000 after acquiring an additional 362 shares during the period. Larson Financial Group LLC grew its position in shares of QuidelOrtho by 322.2% during the 3rd quarter. Larson Financial Group LLC now owns 1,330 shares of the company’s stock valued at $39,000 after acquiring an additional 1,015 shares during the period. Finally, Leonteq Securities AG increased its stake in shares of QuidelOrtho by 555.2% in the 1st quarter. Leonteq Securities AG now owns 3,466 shares of the company’s stock worth $57,000 after purchasing an additional 2,937 shares in the last quarter. 99.00% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on QDEL shares. Citigroup raised their target price on QuidelOrtho from $13.00 to $18.00 and gave the stock a “neutral” rating in a report on Wednesday, July 8th. Wall Street Zen raised QuidelOrtho from a “sell” rating to a “hold” rating in a report on Sunday, June 28th. Weiss Ratings restated a “sell (e+)” rating on shares of QuidelOrtho in a research report on Tuesday, April 21st. UBS Group reaffirmed a “neutral” rating and issued a $12.00 price objective on shares of QuidelOrtho in a research note on Thursday, May 7th. Finally, JPMorgan Chase & Co. lifted their price objective on QuidelOrtho from $11.00 to $12.00 and gave the company an “underweight” rating in a research report on Wednesday, July 1st. Four investment analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Reduce” and a consensus target price of $13.62.

QuidelOrtho Stock Performance

NASDAQ QDEL opened at $18.24 on Friday. The firm has a market cap of $1.24 billion, a price-to-earnings ratio of -1.02 and a beta of 0.69. The company has a quick ratio of 0.80, a current ratio of 1.43 and a debt-to-equity ratio of 1.33. The business has a 50-day moving average price of $14.17 and a 200-day moving average price of $19.17. QuidelOrtho Corporation has a twelve month low of $9.92 and a twelve month high of $35.58.

QuidelOrtho (NASDAQ:QDEL) last issued its earnings results on Tuesday, May 5th. The company reported ($0.04) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.37 by ($0.41). QuidelOrtho had a negative net margin of 45.57% and a positive return on equity of 4.25%. The business had revenue of $619.80 million for the quarter, compared to the consensus estimate of $665.23 million. During the same period last year, the business posted $0.74 EPS. The firm’s revenue for the quarter was down 10.5% compared to the same quarter last year. QuidelOrtho has set its FY 2026 guidance at 1.800-2.000 EPS. As a group, equities research analysts predict that QuidelOrtho Corporation will post 1.87 EPS for the current fiscal year.

QuidelOrtho Profile

QuidelOrtho is a global diagnostics company formed through the merger of Quidel Corporation and Ortho Clinical Diagnostics. The combined entity develops, manufactures and markets a broad portfolio of rapid and high-throughput diagnostic solutions across immunoassay, molecular diagnostics and transfusion medicine. Its offerings span point-of-care platforms for acute care testing as well as large-scale automated systems designed for clinical laboratories and blood banks.

The company’s product range includes rapid antigen and antibody tests for infectious diseases, molecular assays utilizing nucleic acid amplification technology, and integrated immunodiagnostic analyzers.